Guobang Pharma Ltd(605507) ( Guobang Pharma Ltd(605507) ) announced on the evening of March 17 that the 13th meeting of the first board of directors of the company considered and approved the proposal on the investment and construction of 6000 tons of sodium borohydride, 8500 tons of methyl chlorobutyrate and 89500 tons of related intermediates by wholly-owned subsidiaries, It is agreed that Shandong Guobang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, will invest about 360 million yuan to build a project with an annual output of 6000 tons of sodium borohydride, 8500 tons of methyl chlorobutyrate and 89500 tons of related intermediates.
The announcement shows that the above-mentioned projects are constructed in two phases. After the completion of the first phase, the annual production capacity of 6000 tons of sodium borohydride, 40000 tons of liquid sodium borohydride and 40000 tons of trimethyl borate will be formed; After the completion of phase II, an annual output of 8500 tons will be formed γ- The production capacity of methyl chlorobutyrate, 3000 tons of chlorobutyryl chloride, 5000 tons of sodium tert butyl alcohol and 1500 tons of triisopropyl borate.
Guobang Pharma Ltd(605507) said that the investment project is in line with the company’s strategic business direction and is conducive to expanding the company’s existing production capacity; At the same time, it is also conducive for the company to take advantage of the technology and cost advantages brought by large-scale manufacturing, seize the development opportunities of fine chemicals and pharmaceutical intermediates market, actively extend the industrial chain, further improve the company’s market share, enhance the company’s competitiveness and influence, and lay a solid foundation for the company’s future development.
The company also suggested that the investment project will be constructed in two phases, with a construction period of 5 years. At present, it is still in the preparatory stage, and there is uncertainty risk in subsequent equipment installation, commissioning and trial production.
